Somatostatin in Clinical Endocrinology

  • W. W. de Herder
  • S. W. J. Lamberts
Conference paper


The small cyclic peptide hormone, somatostatin (ss), is present in the human body in two molecular forms: somatostatin-14 (consisting of 14 amino acids) and somatostatin-28 (28 amino acids). It exerts diverse biologic effects through interaction with specific somatostatin receptors (ssts) in its target tissues. Ss acts as an inhibitor of endocrine and exocrine secretory processes, neurotransmission and as an immune modulation (Lamberts et al., 1996). Ssts belong to the family of G-protein coupled receptors, which characteristically consist of a single polypeptide chain with seven transmembrane spanning domains: extracellular domains with ligand binding sites and intracellular domains with sites linked to the activation of second messengers. At present, five different human sst subtypes (sst1, sst2, sst3, sst4, and sst5) have been cloned and characterised (Patel, 1999). Ssts are encoded by five different genes, each with a distinct chromosomal localization. Although the different sst subtypes are 40% to 60% structurally homologous, each sst subtype mediates different biologic actions of somatostatin. The inhibitory effects of somatostatin or its analogs, mediated via ssts, are linked with several intra-cellular systems: inhibition of adenylyl cyclase, resulting in a decrease in the intracellular cyclic AMP levels; reduction of Ca2+ influxes, resulting in reduced intracellular Ca2+ levels; and, in a number of tissues, stimulation of tyrosine phosphatase activity.


Medullary Thyroid Carcinoma Clinical Endocrinology Islet Cell Tumor Gastrointestinal Neuroendocrine Tumor Medullary Thyroid Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnold R., Simon B. and Wied M. (2000). Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion, 62 (Suppl 1), 84–91.PubMedCrossRefGoogle Scholar
  2. Beck-Peccoz P., Brucker-Davis R, Persani L., Smallridge R.C. and Weintraub B.D. (1996). Thyrotropin-secreting pituitary tumors. Endocr Rev, 17, 610–638.PubMedGoogle Scholar
  3. Benali N., Ferjoux G., Puente E., Buscail L. and Susini C. (2000a). Somatostatin receptors. Digestion, 62 (Suppl 1), 27–32.CrossRefGoogle Scholar
  4. Benali N., Cordelier P., Calise D., Pages P., Rochaix P., Nagy A., Esteve J.P., Pour P.M., Schally A.V., Vaysse N., Susini C. and Buscail L. (2000b). Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Nat Acad Sei USA, 97, 9180–9185.CrossRefGoogle Scholar
  5. Benevento A., Dominioni L., Carcano G. and Dionigi R. (1998). Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe. Semin Surg Oncol, 15, 239–244.PubMedCrossRefGoogle Scholar
  6. Bousquet C., Puente E., Buscail L., Vaysse N. and Susini C. (2001). Antiproliferative effect of somatostatin and analogs. Chemotherapy, 47 (Suppl 2), 30–39.PubMedCrossRefGoogle Scholar
  7. Bruns C, Lewis I., Briner U., Meno-Tetang G. and Weckbecker G. (2002). SOM230: a new somatostatin peptidomimetic with a broad SRIF receptor binding and a unique inhibitory profile. Eur J Endocrinol, 146, 707–716.PubMedCrossRefGoogle Scholar
  8. Caplin M.E., Buscombe J.R., Hilson A.J., Jones A.L., Watkinson A.R and Burroughs A.K. (1998) Carcinoid tumour. Lancet, 352, 799–805.PubMedCrossRefGoogle Scholar
  9. Chanson P., Boerlin V., Ajzenberg C, Bachelot Y., Benito P., Bringer J., Caron P., Charbonnel B., Cortet C, Delemer B., Escobar-Jimenez F., Foubert L., Gaztambide S., Jockenhoevel F., Kuhn J.M., Leclere J., Lorcy Y., Perlemuter L., Prestele H., Roger P., Rohmer V., Santen R., Sassolas G., Scherbaum W.A., Schopohl J., Torres E., Varela C, Villamil R and Webb S.M (2000). Comparison of octreotide acetate LAR and lan-reotide SR in patients with acromegaly. Clin Endocrinol (Oxford), 53, 577–586.CrossRefGoogle Scholar
  10. de Herder W.W. and Lamberts S.W.J. (1995). Imaging of pituitary tumours. Baillieres Clin Endocrinol Metabolism, 9, 367–389.CrossRefGoogle Scholar
  11. de Herder W.W., van der Lely A.J. and Lamberts S.W.J. (1996). Somatostatin analogue treatment of neuroendocrine tumors. Postgrad Med J, 72, 403–408.PubMedCrossRefGoogle Scholar
  12. de Herder W.W., Hofland L.J., van der Lely A.J. and Lamberts S.W. (1996). Peptide receptors in gut endocrine tumours. Baillieres Clinical Gastroenterology, 10, 571–587.CrossRefGoogle Scholar
  13. de Jong M., Breeman W.A., Bernard B.R, Bakker W.H., Schaar M., van Gameren A., Bugaj J.E., Erion J., Schmidt M., Srinivasan A. and Krenning E.P. (2001). [177Lu-DOTA(o), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer, 92, 628–633.PubMedCrossRefGoogle Scholar
  14. Hofland L.J., Breeman W.A., Krenning E.P., de Jong M., Waaijers M., van Koetsveld P.M., Macke H.R. and Lamberts S.W. (1999). Internalization of [DOTA, 125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physician, 111, 63–69.CrossRefGoogle Scholar
  15. Ingle J.N., Suman V.J., Kardinal CG., Krook J.E., Mailliard J.A., Veeder M.H., Loprinzi CL., Dalton R.J., Hartmann L.C., Conover C.A. and Pollak M.N. (1999). A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer, 85, 1284–1292.PubMedCrossRefGoogle Scholar
  16. Jenkins S.A., Kynaston H.G., Davies N.D., Baxter J.N. and Nott D.M. (2001). Somatostatin analogs in oncology: a look to the future. Chemotherapy, 47 (Suppl 2), 162–196.PubMedCrossRefGoogle Scholar
  17. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hagen M., Postema P.T., de Jong M. and Reubi J.C., (1993)- Somatostatin receptor scintigraphy with [111In-DTPA-D-Phei]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 20, 716–731.PubMedCrossRefGoogle Scholar
  18. Krenning E.P., de Jong M., Kooij P.P., Breeman W.A., Bakker W.H., de Herder W.W., van Eijck C.H., Kwekkeboom D.J., Jamar F., Pauwels S. and Valkema R. (1999). Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radio nuclide therapy. Ann Oncol, 10 (Suppl 2), S23–S29.PubMedCrossRefGoogle Scholar
  19. Kvols L.K., Moertel C.G., O’Connell M.J., Schutt A.J., Rubin J. and Hahn R.G. (1986). Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. New Engl J Med, 315, 663–666.PubMedCrossRefGoogle Scholar
  20. Kwekkeboom D.J., de Herder W.W. and Krenning E.P. (1999). Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest, 22, 80–88.PubMedGoogle Scholar
  21. Kwekkeboom D., Krenning E.P. and de Jong M. (2000). Peptide receptor imaging and therapy. J Nucl Med, 41, 1704–1713.PubMedGoogle Scholar
  22. Kwekkeboom D.J., Bakker W.H., Kam B.L., Teunissen J.J.M., Kooij P.P.M., Herder W.W., Feelders R.A., Eijck C.H.J., Jong M., Srinivasan A., Erion J.L. and Krenning E.P. (2003). Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTAo,Tyr3] octreotate. Eur J Nucl Med, 30, 417–422.CrossRefGoogle Scholar
  23. Lamberts S.W.J., van der Lely A.J., de Herder W.W. and Hofland L.J. (1996). Octreotide. New Engl J Med, 334, 246–254.PubMedCrossRefGoogle Scholar
  24. Lamberts S.W.J., Hofland L.J. and Nobels F.R. (2001) Neuroendocrine tumor markers. Frontiers Neuroendocrinology, 22, 309–339.CrossRefGoogle Scholar
  25. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P,YoungW, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W,Jackson I, Vance ML,Barkan A, Frohman L and Kleinberg DL. (1998). Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology & Metabolism, 83, 3034–3040.CrossRefGoogle Scholar
  26. ?berg K. (2001). Established clinical use of octreotide and lanreotide in oncology. Chemotherapy, 47 (Suppl 2), 40–53.PubMedGoogle Scholar
  27. Patel Y.C. (1999). Somatostatin and its receptor family. Frontiers Neuroendocrinology, 20, 157–198.CrossRefGoogle Scholar
  28. Ren, S., Culler M., Heany T. and Melmed S. (2000). Functional association of sstr2, and sstr5, in suppression of growth hormone secretion. The Endocrine Society Denver, 339 abstract.Google Scholar
  29. Rocheville M., Lange D.C., Kumar U., Sasi R., Patel R.C. and Patel Y.C. (2000a). Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem, 275, 7862–7869.CrossRefGoogle Scholar
  30. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C. and Patel Y.C. (2000b). Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity [see comments). Science, 288, 154–157.CrossRefGoogle Scholar
  31. Ruszniewski P., Ducreux M., Chayvialle J.A., Blumberg J., Cloarec D., Michel H., Raymond J.M., Dupas J.L., Gouerou H., Jian R., Genestin E., Bernades P.and Rougier P. (1996). Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut, 39, 279–283.PubMedCrossRefGoogle Scholar
  32. Saveanu A., Gunz G., Dufour H., Caron P., Fina F., Ouafik L., Culler M.D., Moreau J.P., Enjalbert A. and Iaquet P. (2001). Bim-23244,a somatostatin receptor subtype 2- and 5selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology & Metabolism, 86, 140–145.CrossRefGoogle Scholar
  33. Scarpignato C. and Pelosini I. (2001). Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy, 47 (Suppl z), 1–29.PubMedCrossRefGoogle Scholar
  34. Sharma, K., Patel Y.C. and Srikat C.B. (1996). Subtype-selective induction of wild-type P53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol, 10, 1688–1696.PubMedCrossRefGoogle Scholar
  35. Smith M.C., Liu J., Chen T., Schran H., Yeh C.M., Jamar F.,Valkema R., Bakker W., Kvols L., Krenning E. and Pauwels S. (2000). OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion, 62 (Suppl 1), 69–72.PubMedCrossRefGoogle Scholar
  36. Tiensuu Janson E.T., Westlin J.E., Eriksson B., Ahlstrom H., Nilsson S and Oberg K. (1994). [111111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol, 131, 577–581.CrossRefGoogle Scholar
  37. Trendle M.C., Moertel C.G. and Kvols L.K. (1997). Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer, 79, 830–834.PubMedCrossRefGoogle Scholar
  38. van Eijck, C.H. Krenning E.P., Bootsma A.H., Oei H.Y., van Pel R.. Lindemans J., Jeekel J.J., Reubi J.C and Lamberts S.W. (1994). Somatostatin-receptor scintigraphy in primary breast cancer [see comments]. Lancet, 343, 640–643.PubMedCrossRefGoogle Scholar
  39. Verhelst J.A., Pedroncelli A.M., Abs R., Montini M., Vandeweghe M.V., Albani G., Maiter D., Pagani M.D., Legros J.J., Gianola D., Bex M., Poppe K., Mockel J. and Pagani G.(2000). Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol, 143, 577–584.PubMedCrossRefGoogle Scholar
  40. Virgolini L, Traub T., Leimer M., Novotny C, Pangerl T., Ofluoglu S., Halvadjieva E., Smith-Jones P., Flores J., Li S.R., Angelberger P., Havlik E., Andreae F., Raderer M., Kurtaran A., Niederle B. and Dudczak R.(2000). New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q Journal of Nuclear Medicine, 44, 50–58.Google Scholar
  41. Warnet A., Harris A.G., Renard E., Martin D., James-Deidier A. and Chaumet-Riffaud P. (1997). A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group. Neurosurgery, 41, 786–795.PubMedCrossRefGoogle Scholar
  42. Wymenga A.N., Eriksson B., Salmela P.I., Jacobsen M.B., Van Cutsem E.J., Fiasse R.H., Valimaki M.J., Renstrup J., de Vries E.G. and Oberg K.E. (1999). Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol, 17, 1111.PubMedGoogle Scholar
  43. Zatelli M.C, Tagliati F., Taylor J.E., Rossi R., Culler M.D. and Uberti E.C (2001). Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. Journal of Clinical Endocrinology & Metabolism, 86, 2161–2169.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • W. W. de Herder
  • S. W. J. Lamberts

There are no affiliations available

Personalised recommendations